Strategies for Streamlining Small Molecule Formulation Development When Bridging from Candidate Selection to First-in-Human Clinical Testing
Small molecules continue to dominate over biologics in new pharmaceutical product launches. According to the US Food and Drug Administration’s Center for Drug Evaluation and Research in 2021 small molecules comprised 33 of the 50 approvals. So, how do drug developers like Quotient Sciences know which strategy and approach is right for their partners molecule at this early stage?
In a recent article with Pharmaceutical Technology, Stephen Byard, Principal Research Fellow, Science & Technology, Candidate Development at Quotient Sciences shared his thoughts on the strategies we use for streamlining small molecule formulation development when bridging from candidate selection to first-in-human clinical testing.